CN Patent

CN110804058B — 一种伊布替尼新晶型及其制备方法

Assigned to Lunan Pharmaceutical Group Corp · Expires 2022-11-11 · 4y expired

What this patent protects

本发明属于医药化工领域，涉及一种伊布替尼的晶型M及其制备方法，该晶型的X‑射线粉末衍射2θ值在5.1±0.2°、5.7±0.2°、12.2±0.2°、15.2±0.2°、18.9±0.2°、20.3±0.2°、21.3±0.2°、21.7±0.2°处有特征衍射峰。该晶型物纯度高，稳定性好，制备方法简单，易于操作，适合工业化生产。

USPTO Abstract

本发明属于医药化工领域，涉及一种伊布替尼的晶型M及其制备方法，该晶型的X‑射线粉末衍射2θ值在5.1±0.2°、5.7±0.2°、12.2±0.2°、15.2±0.2°、18.9±0.2°、20.3±0.2°、21.3±0.2°、21.7±0.2°处有特征衍射峰。该晶型物纯度高，稳定性好，制备方法简单，易于操作，适合工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN110804058B
Jurisdiction
CN
Classification
—
Expires
2022-11-11
Drug substance claim
No
Drug product claim
No
Assignee
Lunan Pharmaceutical Group Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.